

GENETICS

Comprehensive Analysis of Genetic Contributions to Alzheimer's Disease and Frontotemporal Dementia in Admixed Latin American Populations

Juliana Acosta-Uribe^{1,2} | Stefanie Danielle Pina Escudero^{3,4} | J. Nicholas Cochran⁵ | Jared W Taylor⁵ | Caroline Warly Solsberg⁶ | Diana Matallana^{7,8,9} | Leonel Tadao Takada¹⁰ | Martín Alejandro Bruno^{11,12} | Alexandra R. Levine¹³ | Dawwod S. George¹³ | Francisco Lopera¹⁴ | Andrea Slachevsky Chonchol^{15,16,17,18} | María Isabel Behrens^{19,20} | José Alberto Ávila Funes²¹ | Lina Maria Zapata-Restrepo^{22,23} | Luis Ignacio Brusco^{24,25} | Nilton Custodio²⁶ | Teresita Ramos Franco²⁷ | Bárbara Bruna¹⁹ | Daniela P Ponce¹⁹ | Nancy Gelvez⁷ | Greizy Lopez⁷ | Luisa Gomez²⁸ | Carlos Felipe Buitrago²⁹ | Pablo A Reyes³⁰ | Dafne Estefania Durón³¹ | Caroline Pantazis³² | Marcelo Adrian Maito³³ | Shireen Javandel⁴ | Maria Eugenia Godoy³⁴ | Maria Beatriz Bistue Millon^{35,36,37} | Dan Vitale³⁸ | Mike A Nalls³⁸ | Andrew Singleton^{32,39} | Bruce L. Miller^{6,40} | Agustín Ibáñez^{41,42} | Kenneth S. Kosik¹ | Jennifer S. Yokoyama^{4,43} | Rosa Montesinos^{44,45} | Elisa de Paula França Resende^{46,47} | Multi-Partner Consortium to Expand Dementia Research in Latin America (ReDLat)

¹University of California Santa Barbara, Santa Barbara, CA, USA²Neurosciences Group of Antioquia, University of Antioquia, Medellín, Colombia³Global Brain Health Institute (GBHI), University of California, San Francisco, USA⁴University of California, San Francisco, San Francisco, CA, USA⁵HudsonAlpha Institute for Biotechnology, Huntsville, AL, USA⁶University of California San Francisco, San Francisco, CA, USA⁷Pontificia Universidad Javeriana, Bogota, Cundinamarca, Colombia⁸Hospital Universitario San Ignacio, Bogotá, Colombia⁹Hospital Universitario Fundación Santa Fe, Bogotá, Colombia¹⁰Hospital das Clínicas, University of Sao Paulo Medical School, São Paulo, Brazil¹¹Instituto de Ciencias Biomédicas (ICBM) Facultad de Ciencias Médicas, Universidad Catoóica de Cuyo, San Juan, Argentina¹²CONICET, San Juan, Argentina¹³University of California, Santa Barbara, Santa Barbara, CA, USA¹⁴Grupo de Neurociencias de Antioquia, Facultad de Medicina, Universidad de Antioquia, Medellín, Colombia

This is an open access article under the terms of the [Creative Commons Attribution](https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

© 2024 The Alzheimer's Association. *Alzheimer's & Dementia* published by Wiley Periodicals LLC on behalf of Alzheimer's Association.

- ¹⁵Neurology Service, Department of Medicine, Clínica Alemana-Universidad del Desarrollo, Santiago, Chile., Santiago, Chile
- ¹⁶Neuropsychology and Clinical Neuroscience Laboratory (LANNEC), Physiopathology Department - ICBM, Neuroscience and East Neuroscience Departments, Faculty of Medicine, Universidad de Chile, Santiago, Chile
- ¹⁷Geroscience Center for Brain Health and Metabolism (GERO), Santiago, Chile
- ¹⁸Memory and Neuropsychiatric Center (CMYN), Neurology Department, Hospital del Salvador and Faculty of Medicine, Universidad de Chile, Santiago, Chile
- ¹⁹Centro de Investigación Clínica Avanza (CICA), Hospital Clínico Universidad de Chile, Santiago, Chile
- ²⁰Hospital Clínico de la Universidad de Chile, Santiago de Chile, Chile
- ²¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, DF, Mexico
- ²²Facultad de Ciencias de la Salud, Universidad Icesi, Cali, Colombia, Cali, Colombia
- ²³Fundación Valle del Lili, Cali, Colombia
- ²⁴ALZAR - Argentine Alzheimer's Association, Buenos Aires, CABA, Argentina
- ²⁵Universidad de Buenos Aires, Buenos Aires, Argentina
- ²⁶Instituto Peruano de Neurociencias, Lima, Lima, Peru
- ²⁷Hospital del Salvador & Faculty of Medicine, University of Chile., Santiago, Chile
- ²⁸Pontificia Universidad Javeriana, Bogotá, Colombia
- ²⁹Pontificia Universidad Javeriana, Bogotá, Cundinamarca, Colombia
- ³⁰Pontificia Universidad Javeriana, Bogota, Colombia
- ³¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Ciudad de México, DF, Mexico
- ³²Center for Alzheimer's and Related Dementias, National Institute on Aging and National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA
- ³³Latin American Brain Health Institute (BrainLat), Universidad Adolfo Ibañez, Santiago, Chile
- ³⁴Universidad de San Andres, Buenos Aires, Argentina
- ³⁵Universidad Católica de Cuyo / CONICET, San Juan, Argentina
- ³⁶Instituto de Ciencias Biomédicas (ICBM), Facultad de Ciencias Médicas, Universidad Católica de Cuyo, San Juan, Argentina
- ³⁷CONICET, San Juan, Argentina
- ³⁸Data Tecnica International, Washington, DC, USA
- ³⁹National Institute on Aging, National Institutes of Health, Bethesda, MD, USA
- ⁴⁰Global Brain Health Institute, San Francisco, CA, USA
- ⁴¹BrainLat Institute, Santiago, Santiago, Chile
- ⁴²Global Brain Health Institute, Trinity College Dublin, Dublin, Ireland
- ⁴³Global Brain Health Institute, University of California San Francisco, San Francisco, CA, USA
- ⁴⁴Unit Cognitive Impairment and Dementia Prevention, Peruvian Institute of Neurosciences, Lima, Peru, Lima, Lima, Peru
- ⁴⁵Research unit, Instituto Peruano de Neurociencias, Lima, Peru
- ⁴⁶Faculdade de Medicina de Ciências Médicas de Minas Gerais, Belo Horizonte, Brazil
- ⁴⁷Global Brain Health Institute, University of California, San Francisco, CA, USA

Correspondence

Juliana Acosta-Urbe, University of California
Santa Barbara, Santa Barbara, CA, USA.
Email: acostauribe@ucsb.edu

Abstract

Background: Most research initiatives have emerged from high-income countries (HIC), leaving a gap in understanding the disease's genetic basis in diverse populations like those in Latin American countries (LAC). ReDLat tackles this gap, focusing on LAC's unique genetics and socioeconomic factors to identify specific Alzheimer's Disease (AD) and Frontotemporal Dementia (FTD) risk factors in Mexico, Colombia, Peru, Chile, Argentina, and Brazil.

Method: We employed a comprehensive genetic analysis approach, integrating Whole Genome Sequencing (WGS), Exome Sequencing, and SNP arrays to understand the cohort's unique genetic architecture. We conducted ancestry analysis and searched for disease-causing variants with mendelian inheritance, genome-wide association studies (GWAS), rare variant enrichment, and evaluation of Polygenic Risk Scores (PRS).

Results: We recruited and genotyped an initial cohort of 1046 participants with AD, 423 with FTD, and 855 healthy controls (HC) between 2020 and 2023. Analysis is ongoing, and we expect to sequence ~600 additional samples in the coming months. Ancestry analysis revealed tri-continental admixture, except for Brazil, which showed an additional Asian component (Figure 1). Top candidate gene rare variant enrichment associations (SKAT $p < 0.05$) were *TREM2* for FTD and *ABCA7* and *ABCA1* for AD. GWAS identified a robust association with the *APOE* locus on chromosome 19 in AD vs. HC. We tested an AD PRS developed in European populations by Bellenguez et al (2020) on our cohort using 83 single-nucleotide polymorphisms. The PRS modestly distinguishes between all patients and HC ($p = 2.4 \times 10^{-12}$), AD vs. HC ($p = 2.2 \times 10^{-12}$), and even FTD vs. HC ($p = 4.3 \times 10^{-5}$), albeit with modest separation between groups, as expected for its application in a genetically admixed population.

Conclusion: Our findings represent a pivotal step in understanding the genetic landscape of AD and FTD in admixed populations. They underscore the importance of including diverse populations in genetic research, paving the way for future studies. These findings have the potential to inform more personalized approaches to the diagnosis and treatment of neurodegenerative diseases in diverse global populations, as well as identify novel targets for therapeutic development.

